ES2122248T3 - Inhibicion de la hiperplasia de la intima que emplea anticuerpos de receptores del factor de crecimiento derivado de plaquetas. - Google Patents

Inhibicion de la hiperplasia de la intima que emplea anticuerpos de receptores del factor de crecimiento derivado de plaquetas.

Info

Publication number
ES2122248T3
ES2122248T3 ES94909627T ES94909627T ES2122248T3 ES 2122248 T3 ES2122248 T3 ES 2122248T3 ES 94909627 T ES94909627 T ES 94909627T ES 94909627 T ES94909627 T ES 94909627T ES 2122248 T3 ES2122248 T3 ES 2122248T3
Authority
ES
Spain
Prior art keywords
hyperplasia
platelets
intimate
receptors
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909627T
Other languages
English (en)
Inventor
Charles E Hart
Richard D Kenagy
Alexander W Clowes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Zymogenetics Inc
Original Assignee
University of Washington
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Zymogenetics Inc filed Critical University of Washington
Application granted granted Critical
Publication of ES2122248T3 publication Critical patent/ES2122248T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN METODOS DE INHIBICION DE HIPERPLASIA INTIMA EN LA VASCULATURA DE MAMIFEROS, INCLUYENDO PRIMATES. LOS METODOS COMPRENDEN LA ADMINISTRACION AL MAMIFERO DE UN ANTICUERPO RECEPTOR ANTI-PDGF, COMO UN ANTICUERPO RECEPTOR ANTI-PDGF-ALFA O UN ANTICUERPO RECEPTOR ANTI-PDGF-BETA. LOS METODOS SON UTILES EN LA REDUCCION DE LA HIPERPLASIA INTIMA DEBIDO A, POR EJEMPLO, LESIONES VASCULARES RESULTANTES DE ANGIOPLASTIA, ENDARTERECTOMIA, ATERECTOMIA DE REDUCCION O ANASTOMOSIS DE UN INJERTO VASCULAR.
ES94909627T 1993-02-25 1994-02-17 Inhibicion de la hiperplasia de la intima que emplea anticuerpos de receptores del factor de crecimiento derivado de plaquetas. Expired - Lifetime ES2122248T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2350493A 1993-02-25 1993-02-25

Publications (1)

Publication Number Publication Date
ES2122248T3 true ES2122248T3 (es) 1998-12-16

Family

ID=21815476

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909627T Expired - Lifetime ES2122248T3 (es) 1993-02-25 1994-02-17 Inhibicion de la hiperplasia de la intima que emplea anticuerpos de receptores del factor de crecimiento derivado de plaquetas.

Country Status (8)

Country Link
EP (1) EP0686044B1 (es)
JP (1) JP2944218B2 (es)
AT (1) ATE170402T1 (es)
CA (1) CA2156825C (es)
DE (1) DE69413009T2 (es)
DK (1) DK0686044T3 (es)
ES (1) ES2122248T3 (es)
WO (1) WO1994019016A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
WO1998035697A1 (en) * 1997-02-14 1998-08-20 Roche Diagnostics Gmbh Improved method for the reduction of neointima formation after angioplasty
AU1454199A (en) * 1997-11-07 1999-05-31 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
CA2396628A1 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6990848B2 (en) * 2002-08-05 2006-01-31 Trxoler Electronic Laboratories, Inc. System and method for determining material properties of samples
EP2100618B1 (en) 2005-06-17 2014-02-12 ImClone LLC An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619738B1 (en) * 1991-12-02 2003-07-09 Millennium Pharmaceuticals, Inc. Inhibitory immunoglobulin polypeptides to human pdgf beta receptor

Also Published As

Publication number Publication date
DE69413009T2 (de) 1999-03-25
DK0686044T3 (da) 2000-10-09
EP0686044B1 (en) 1998-09-02
JPH08507063A (ja) 1996-07-30
ATE170402T1 (de) 1998-09-15
DE69413009D1 (de) 1998-10-08
EP0686044A1 (en) 1995-12-13
CA2156825C (en) 2003-10-21
CA2156825A1 (en) 1994-09-01
WO1994019016A1 (en) 1994-09-01
JP2944218B2 (ja) 1999-08-30

Similar Documents

Publication Publication Date Title
GB2311463B (en) Composition for inhibiting intimal hyperplasia using PDGF antagonists and heparin
ES2161751T3 (es) Anticuerpo monoclonal que se une especificamente al endotelio vascular tumoral y usos del mismo.
AU5938696A (en) 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
BG101647A (en) Low molecular weight bicyclic thrombin inhibitors
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
ES2122248T3 (es) Inhibicion de la hiperplasia de la intima que emplea anticuerpos de receptores del factor de crecimiento derivado de plaquetas.
HK55797A (en) Fluoro substituted benzocycloheptapyridine compounds compositions and methods of use as antihistaminic compounds
DE69133179T2 (de) Katalytische antikörperkomponente
DK331287D0 (da) Praeparater til hindring af transplantationsudstoedelse
AU6048396A (en) Use of brefeldin a and derivatives thereof in the treatment of hyperplasia and related disorders
ATE263187T1 (de) Neuartige heparin bindende peptide
HK1010395A1 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins.
ATE169227T1 (de) Hemmung von gefässverengung unter verwendung von anti-padgem antikörpern.
DK226889D0 (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
NO904292L (no) Fremgangsmaate for fremstilling av antikoagulerende peptider.
NO894880L (no) Fremgangsmaate for fremstilling av antikoagulerende peptider.
DK523589A (da) Immuntoxiner til behandling af eller forebyggelse mod autoimmunsygdomme
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
ES2097160T3 (es) Anticuerpos monoclonales anti-oncostantina m.
FR2697154B1 (fr) Perfectionnement au composant fémoral des prothèse du genou.
IT1250430B (it) Inibitori dell'adesione piastrinica al fattore von willebrand e loro uso come farmaci antitrombotici

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686044

Country of ref document: ES